Voriconazole: Poor oral bioavailability and possible renal toxicity in an infant with invasive aspergillosis
JournalJournal of Pediatric Pharmacology and Therapeutics
PublisherPediatric Pharmacy Advocacy Group, Inc.
MetadataShow full item record
AbstractVoriconazole is the recommended agent of choice for treatment of invasive aspergillosis; however, achieving therapeutic serum concentrations while avoiding toxicity, both with intravenous and oral formulations, is challenging in infants. We report the case of an infant with confirmed invasive aspergillosis who developed renal toxicity possibly associated with IV voriconazole. Renal function improved upon withdrawal of the IV agent and switch to the oral formulation. The infant subsequently required large oral weight-based dosing to achieve therapeutic voriconazole serum concentrations. This case illustrates a rare side effect associated with voriconazole as well as the issues surrounding the pharmacokinetic profile of voriconazole in a pediatric patient. Copyright Published by the Pediatric Pharmacy Advocacy Group. All rights reserved.
Drug-related side effects
Therapeutic drug monitoring
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85044231754&doi=10.5863%2f1551-6776-23.1.54&partnerID=40&md5=5f3f9340babf57aedb82b770bed02ef4; http://hdl.handle.net/10713/9024